<rss version="2.0">
<channel>
<title>MindBranch: Pharmaceutical</title>
<description>Pharmaceutical market research products provide analysis of the latest trends, developments and market data for this industry.  Research information will help you make informed business decisions.</description>
<link>http://www.mindbranch.com/catalog/find.jsp?cat=ph</link>
<item>
<title>From No's and Low's to Positive Eating: Weight Management Trends in the U.S.</title>
<link>http://www.mindbranch.com/products/R567-787.html</link>
<description> <![CDATA[Dieting, that American pastime that nearly all adults and many children and adolescents have tried at one time or another has lost its luster in recent years.  Experts describe the decline as being the result of years of fad diets that simply haven&rsquo;t worked.   This notion that fad diets don&rsquo;t work and more importantly  can&rsquo;t work  is supported by impressive and relatively recent science focused in the areas of genetics and hormones.  There are still many unanswered questions, but a new picture of how weight regulation works is emerging and it has little to do with will power and more to do with lucky genes.  Packaged Facts believes that consumers are beginning to embrace the idea of setting a realistic target weight and adopting a healthy diet along with moderate exercise in lieu of unrealistic weight targets and fad diets.  Food is to be ]]></description>
<pubDate>Fri, 01 Jan 2010 00:00:00 EST</pubDate>
</item>
<item>
<title>Pharmaceutical Manufacturers Report - Chinese</title>
<link>http://www.mindbranch.com/products/R3468-11464.html</link>
<description> <![CDATA[The Chinese Pharmaceutical Manufacturers Report Plimsoll Publishing Ltd.  Do you know.... The top 7 best trading partners in the industry? Which company has the highest sales growth? Which companies have the highest levels of debt?  This report is an in-depth financial evaluation of the Chinese Pharmaceutical Manufacturers Industry. Using the unique Plimsoll method of analysis, each of the top 1000 Chinese Pharmaceutical Manufacturers is individually assessed and ranked against each other and compared to industry averages. Using the most up-to-date financial information available, the two-page analysis provides detailed financial analysis for each organisation, including details of;    Sales growth    Trading stability   Profitability    Employee performance   Level of debt   Gearing ratio&rsquo;s   Creditor Exposure   Performance ratio&rsquo;s   Overall financial rating  Results are shown in graphical, numeric and narrative forms, and all individual analysis are measured in both the company&rsquo;s own currency, and USD ($) for ease of use. These individual analyses highlight a company&rsquo;s success just as easily as ]]></description>
<pubDate>Sun, 01 Nov 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>Top 50 Pharmaceutical Companies Report</title>
<link>http://www.mindbranch.com/products/R3468-11487.html</link>
<description> <![CDATA[The Global Top 50 Pharmaceutical Companies Report Plimsoll Publishing Ltd.  Do you know.... The top 7 best trading partners in the industry? Which company has the highest sales growth? Which companies have the highest levels of debt?  This report is an in-depth financial evaluation of the Global Top 50 Pharmaceutical Companies. Using the unique Plimsoll method of analysis, each of the top 50 Global Pharmaceutical Companies is individually assessed and ranked against each other and compared to industry averages. Using the most up-to-date financial information available, the two-page analysis provides detailed financial analysis for each organisation, including details of;    Sales growth    Trading stability   Profitability    Employee performance   Level of debt   Gearing ratio&rsquo;s   Creditor Exposure   Performance ratio&rsquo;s   Overall financial rating  Results are shown in graphical, numeric and narrative forms, and all individual analysis are measured in both the company&rsquo;s own currency, and USD ($) for ease of use. These individual analyses highlight a company&rsquo;s success just ]]></description>
<pubDate>Sun, 01 Nov 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>Generic Pharmaceuticals Industry Report</title>
<link>http://www.mindbranch.com/products/R3468-11459.html</link>
<description> <![CDATA[The Global Generic Pharmaceuticals Industry Report Plimsoll Publishing Ltd.  Do you know.... The top 7 best trading partners in the industry? Which company has the highest sales growth? Which companies have the highest levels of debt?  This report is an in-depth financial evaluation of the Global Generic Pharmaceuticals Industry Report. Using the unique Plimsoll method of analysis, each of the top 200 Generic Pharmaceutical Companies is individually assessed and ranked against each other and compared to industry averages. Using the most up-to-date financial information available, the two-page analysis provides detailed financial analysis for each organisation, including details of;    Sales growth    Trading stability   Profitability    Employee performance   Level of debt   Gearing ratio&rsquo;s   Creditor Exposure   Performance ratio&rsquo;s   Overall financial rating  Results are shown in graphical, numeric and narrative forms, and all individual analysis are measured in both the company&rsquo;s own currency, and USD ($) for ease of use. These individual analyses highlight a company&rsquo;s success just as ]]></description>
<pubDate>Sun, 01 Nov 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>Pharmaceuticals Industry Report</title>
<link>http://www.mindbranch.com/products/R3468-11466.html</link>
<description> <![CDATA[The Global Pharmaceuticals Industry Report Plimsoll Publishing Ltd.  Do you know.... The top 7 best trading partners in the industry? Which company has the highest sales growth? Which companies have the highest levels of debt?  This report is an in-depth financial evaluation of the global Pharmaceuticals industry. Using the unique Plimsoll method of analysis, each of the top 500 global Pharmaceuticals Manufacturers is individually assessed and ranked against each other and compared to industry averages. Using the most up-to-date financial information available, the two-page analysis provides detailed financial analysis for each Pharmaceuticals manufacturer, including details of;    Sales growth    Trading stability   Profitability    Employee performance   Level of debt   Gearing ratio&rsquo;s   Creditor Exposure   Performance ratio&rsquo;s   Overall financial rating  Results are shown in graphical, numeric and narrative forms, and all individual analysis are measured in both the company&rsquo;s own currency, and USD ($) for ease of use. These individual analyses highlight a company&rsquo;s success just as easily as ]]></description>
<pubDate>Sun, 01 Nov 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>Point of Care Diagnostics 2010 and Beyond: Rapid Testing at a Crossroads</title>
<link>http://www.mindbranch.com/products/R566-514.html</link>
<description> <![CDATA[As Kalorama Information's lead diagnostic analyst finds, the point of care concept is at a crossroads: the technologies needed to make rapid testing a reality have arrived.   But is healthcare ready?     Kalorama believes that the drive for wellness and the attention surrounding healthcare reform will focus attention on rapid diagnostics. However, according to Shara Rosen, RT, M.B.A., there are many challenges which must be overcome for point of care solutions to be fully utilized, and those companies willing to pivot strategies and best adjust to tomorrow&rsquo;s healthcare marketplace may be rewarded.  
 
This report,  Point of Care Diagnostics 2010: Rapid Testing at a Crossroads  represents the most current analysis of the role POC Diagnostics in today's in vitro industry. Other reports have looked at products, companies and revenue numbers, as this report does. But in her analysis Shara Rosen takes a bold look into ]]></description>
<pubDate>Sun, 01 Nov 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>Pharmaceutical Industry in the United States - Porter&amp;rsquo;s Five Forces Strategy Analysis</title>
<link>http://www.mindbranch.com/products/R3456-373.html</link>
<description> <![CDATA[Pharmaceutical is one of the most intense &ldquo;Knowledge Driven&rdquo; industries, which is continually in a state of dynamic transition.Diversities in life forms and diseases pose stiff challenge to the design of specific and targeted solutions.  The process of &ldquo;drug discovery/invention&rdquo; is elaborate requiring on an average 8-10 years at a cost of US$ 300 million to reach a new drug to the market.  
  
Aruvian's R'search analyzes the Pharmaceutical Industry in United States in the Michael Porter&rsquo;s Five Forces Analysis. It uses concepts developed in Industrial Organization (IO) economics to derive five forces that determine the competitive intensity and therefore attractiveness of a market. Porter referred to these forces as the microenvironment, to contrast it with the more general term macroenvironment. They consist of those forces close to a company that affect its ability to serve its customers and make a profit. A change in any of ]]></description>
<pubDate>Sun, 01 Nov 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>Pharmaceutical Manufacturers Report - Indian</title>
<link>http://www.mindbranch.com/products/R3468-11465.html</link>
<description> <![CDATA[The Indian Pharmaceutical Manufacturers Report Plimsoll Publishing Ltd.  Do you know.... The top 7 best trading partners in the industry? Which company has the highest sales growth? Which companies have the highest levels of debt?  This report is an in-depth financial evaluation of the Indian Pharmaceutical Manufacturers Industry. Using the unique Plimsoll method of analysis, each of the top 200 Indian Pharmaceutical Manufacturers is individually assessed and ranked against each other and compared to industry averages. Using the most up-to-date financial information available, the two-page analysis provides detailed financial analysis for each organisation, including details of;    Sales growth    Trading stability   Profitability    Employee performance   Level of debt   Gearing ratio&rsquo;s   Creditor Exposure   Performance ratio&rsquo;s   Overall financial rating  Results are shown in graphical, numeric and narrative forms, and all individual analysis are measured in both the company&rsquo;s own currency, and USD ($) for ease of use. These individual analyses highlight a company&rsquo;s success just as easily as ]]></description>
<pubDate>Sun, 01 Nov 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>Top 100 Pharmaceutical Manufacturers Industry Analysis</title>
<link>http://www.mindbranch.com/products/R3468-11480.html</link>
<description> <![CDATA[The Global Top 100 Pharmaceutical Industry Report Plimsoll Publishing Ltd.  Do you know.... The top 7 best trading partners in the industry? Which company has the highest sales growth? Which companies have the highest levels of debt?  This report is an in-depth financial evaluation of the Global Top 100 Pharmaceutical Industry. Using the unique Plimsoll method of analysis, each of the Global Top 100 Pharmaceutical Manufacturers is individually assessed and ranked against each other and compared to industry averages. Using the most up-to-date financial information available, the two-page analysis provides detailed financial analysis for each organisation, including details of;    Sales growth    Trading stability   Profitability    Employee performance   Level of debt   Gearing ratio&rsquo;s   Creditor Exposure   Performance ratio&rsquo;s   Overall financial rating  Results are shown in graphical, numeric and narrative forms, and all individual analysis are measured in both the company&rsquo;s own currency, and USD ($) for ease of use. These individual analyses highlight a company&rsquo;s success just ]]></description>
<pubDate>Sun, 01 Nov 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>Freedonia Focus on Biologicals</title>
<link>http://www.mindbranch.com/products/R761-1052.html</link>
<description> <![CDATA[This report discusses US biologicals demand  for the years 2003 and 2008, with forecasts for 2013.  Topics covered include market size, product and market segmentation, technological and product development, regulatory considerations, market environment, product and market forecasts, industry composition and leading participants.  Product segments include recombinant proteins, monoclonal antibodies (Mabs), vaccines, blood and blood derivatives, and other biologicals;  market segments cover pharmacy, ambulatory health care, hospital, other health care markets, and other markets.  This 20 page report also includes a highlights summary and a resources ]]></description>
<pubDate>Sat, 31 Oct 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>Pharmaceutical Manufacturers Show Increased Interest in KPO</title>
<link>http://www.mindbranch.com/products/R104-40352.html</link>
<description> <![CDATA[ This Health Industry Insights Perspective discusses pharmaceutical manufacturers' attitudes toward knowledge process outsourcing ]]></description>
<pubDate>Wed, 21 Oct 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>Lebanon Pharmaceuticals and Healthcare Report Q4 2009</title>
<link>http://www.mindbranch.com/products/R302-8524.html</link>
<description> <![CDATA[We expect total drug spending in Lebanon to increase from under US$500mn in 2008 to US$605mn in2013, a compound annual growth rate (CAGR) of 3.9% in US dollar terms, with 1.75% of GDP dedicatedto pharmaceutical expenditure by 2013.  The Minister of Health, Mohammad Jawad Khalifeh, has held the position since 2005 and hasdramatically reformed drug pricing in the country, highlighting the fact that other countries in the regionwith similar economies were paying significantly less for medicines than Lebanon. Following a lengthyperiod of pressure, the government finally reduced average pharmaceutical prices by 5%, with themomentum and support gained in the process providing the impetus for other regulatory changes,including the introduction of transparency guidelines.  Public sector health provisions have been scrutinised and challenged by Khalifeh in light of high unmetdemand for subsidised services. He said the budget for the Ministry of Public Health in 2005 was only3.5% of GDP and subsequently the department ran ]]></description>
<pubDate>Wed, 21 Oct 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>Substance Abuse &amp; Mental Health Clinics in the US - Industry Market Research Report</title>
<link>http://www.mindbranch.com/products/R538-31382.html</link>
<description> <![CDATA[ Industry Market Research Synopsis   This Industry Market Research report from IBISWorld provides a detailed analysis of the Substance Abuse & Mental Health Clinics in the US industry, including key growth trends, statistics, forecasts, the competitive environment including market shares and the key issues facing the industry.   Industry Definition   This industry comprises establishments with medical staff primarily engaged in providing outpatient services related to the diagnosis and treatment of mental health disorders and alcohol and other substance abuse. These establishments generally treat patients who do not require inpatient treatment. They may provide a counseling staff and information regarding a wide range of mental health and substance abuse issues and/or refer patients to more extensive treatment programs, if necessary.   Report Contents   The Key Statistics chapter provides the key indicators for the industry for at least the last three years. The statistics included are industry revenue, industry gross product, employment, establishments, exports, imports, domestic demand and total wages.  The ]]></description>
<pubDate>Wed, 21 Oct 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>Belarus Pharmaceuticals and Healthcare Report Q4 2009</title>
<link>http://www.mindbranch.com/products/R302-8494.html</link>
<description> <![CDATA[A brief recession and the devaluation of the local currency have demonstrated that Belarus has not beenable to escape the global economic crisis, although sheer lack of integration into the global financialsystem has done much to blunt its impact. According to BMI, the country&rsquo;s pharmaceutical sector isforecast to deliver a five-year compound annual growth rate (CAGR) of 6.47% through to 2013 in USdollar terms (10.75% in local currency terms), with total market value in final consumer prices set toreach US$869mn. At the same time, the market will not see US dollar growth return until 2011, when themarket is expected to resume its previous double-digit growth.  Relations with Russia remain central to overall strength of the Belarusian economy. After a damagingtrade row in July, President Alexander Lukashenko has been eager to push for the implementation of theCustoms Union between the two countries from January 2010, with Kazakhstan also committed to join.In terms ]]></description>
<pubDate>Wed, 21 Oct 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>Pipeline Insight: Colorectal Cancer - Growing trend towards personalized medicine</title>
<link>http://www.mindbranch.com/products/R313-56386.html</link>
<description> <![CDATA[ Introduction   CRC incidence will be over 490,000 cases by 2018 in the seven major markets. This large patient base will translate into a high commercial potential for the development of novel, more effective therapies. Currently, there are 77 agents in development for CRC, 4 of which are in late-phase development. Collectively, they are forecast to achieve sales of $1,398m by 2018.   Scope   Examination of the CRC pipeline with in-depth clinical and commercial profiles of Phase III candidates  Seven major pharmaceutical market sales forecasts for Phase III pipeline products through to 2018  Segmentation and analysis of the current CRC pipeline by developmental phase, drug class and company  Insight and analysis of market potential including commercial opportunity, epidemiology and discussion of unmet needs   Highlights   The CRC pipeline consists of 77 drugs, of which 60% are molecular targeted therapies (MTTs), 22% are immunotherapies, and 17% are cytotoxic therapies. MTTs constitute the bulk of the CRC pipeline. This is in line with ]]></description>
<pubDate>Wed, 21 Oct 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>Kind Snacks Case Study: seeking differentiation in cereal bars with an ethical and healthy offering</title>
<link>http://www.mindbranch.com/products/R313-56778.html</link>
<description> <![CDATA[ Introduction   This case study on Kind Snacks forms part of Datamonitor's case studies series, which explores business practices across a variety of disciplines and business sectors. It looks at how the US cereal bar brand has achieved success by producing bars that have a strong ethical and health positioning.   Reasons to Purchase   Gain insight into the methods used by important industry players to give them a competitive edge  Identify specific areas for operational improvements  Capitalize on the knowledge of experienced companies when entering a new niche or ]]></description>
<pubDate>Tue, 20 Oct 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>Antidiabetics in Australia Market Forecast</title>
<link>http://www.mindbranch.com/products/R313-56415.html</link>
<description> <![CDATA[ Introduction   Datamonitor expects the Australian antidiabetics market to reach $416m by 2018. The growth will be driven by the launch of new drug classes, notably the incretin mimetics, and large growth in patient numbers. Although strongest growth is expected in the non-insulin market, the insulin market will continue to dominate, generating revenues of $224m 10 years from now.   Reasons to Purchase   Identify key opportunities and threats that will impact the use and uptake of new and existing products  Quantify the future size and scope of the Australian antidiabetics market and predict the performance of key compounds  Understand critical success factors in growing and defending antidiabetic brand franchises from new entrants and generics  Please note:   this is delivered as a Zip ]]></description>
<pubDate>Tue, 20 Oct 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>Commercial Insight: Antidiabetics in Australia - Reimbursement status shapes novel classes</title>
<link>http://www.mindbranch.com/products/R313-56394.html</link>
<description> <![CDATA[ Introduction   Datamonitor expects the Australian antidiabetics market to reach $416m by 2018. The growth will be driven by the launch of new drug classes, notably the incretin mimetics, and large growth in patient numbers. Although strongest growth is expected in the non-insulin market, the insulin market will continue to dominate, generating revenues of $224m 10 years from now.   Scope   Forecast for marketed and late-stage pipeline antidiabetic products in Australia  Assessment of Australia-specific drivers and resistors likely to impact the market  Future market outlook for individual products taking into account key market events, in particular patent expiry and competitor launch dates  Case study examining the approval and reimbursement process in Australia in general and for several antidiabetics in specific   Highlights   The Australian antidiabetics market is expected to grow from $233m in 2008 to $416m in 2018 at a rate of 6% CAGR. Significant unmet needs in diabetes fuel a large pipeline. The epidemiological growth of the market, impacted by ]]></description>
<pubDate>Tue, 20 Oct 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>Notable News in the Life Sciences: 3Q09</title>
<link>http://www.mindbranch.com/products/R104-40351.html</link>
<description> <![CDATA[ This Health Industry Insights Perspective provides an unranked list and assessment of important news and trends reported in July through September 2009. (Note also that progress attained or subsequent news reported after the initial announcement may not be included in these analyses.)  In our lead role as life science industry analysts, Health Industry Insights analysts routinely monitor progress and news from across the life science spectrum. Building from monthly assessments of notable announcements, we believe that clients may find value in news and relevant reported progress that we expect are indications of important trends in the industry. As a result, we are issuing quarterly reports that summarize notable published progress in or affecting the life science industry. This update is the eleventh in the ]]></description>
<pubDate>Sun, 18 Oct 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>Substance Abuse &amp; Mental Health Clinics in the US - Industry Risk Rating Report</title>
<link>http://www.mindbranch.com/products/R538-31117.html</link>
<description> <![CDATA[  Industry Risk Ratings Synopsis   This Industry Risk Ratings report from IBISWorld evaluates the inherent risks associated with the Substance Abuse & Mental Health Clinics in the US industry. Industry Risk is assumed to be 'the difficulty, or otherwise, of the business operating environment'.  The report looks at the operational risk associated with this industry. Three types of risk are recognized in our analysis. These are: risk arising from within the industry itself (structural risk), risks arising from the expected future performance of the industry (growth risk) and risk arising from forces external to the industry (external sensitivity risk).  This approach is new in that it analyses non-financial information surrounding each industry. Industries are scored on a 9-point scale, where 1 represents the lowest risk and 9 the highest. The Industry Risk score measures expected Industry Risk over the coming 12-18 months.   Industry Definition   This industry comprises establishments with medical staff primarily engaged in providing outpatient ]]></description>
<pubDate>Sat, 17 Oct 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>Abortion Clinics, Fertility &amp; Family Planning Centers in the US - Industry Risk Rating Report</title>
<link>http://www.mindbranch.com/products/R538-31116.html</link>
<description> <![CDATA[  Industry Risk Ratings Synopsis   This Industry Risk Ratings report from IBISWorld evaluates the inherent risks associated with the Abortion Clinics, Fertility & Family Planning Centers in the US industry. Industry Risk is assumed to be 'the difficulty, or otherwise, of the business operating environment'.  The report looks at the operational risk associated with this industry. Three types of risk are recognized in our analysis. These are: risk arising from within the industry itself (structural risk), risks arising from the expected future performance of the industry (growth risk) and risk arising from forces external to the industry (external sensitivity risk).  This approach is new in that it analyses non-financial information surrounding each industry. Industries are scored on a 9-point scale, where 1 represents the lowest risk and 9 the highest. The Industry Risk score measures expected Industry Risk over the coming 12-18 months.   Industry Definition   This industry includes firms with medical staff primarily engaged in providing ]]></description>
<pubDate>Sat, 17 Oct 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>Chiropractors in the US - Industry Risk Rating Report</title>
<link>http://www.mindbranch.com/products/R538-31111.html</link>
<description> <![CDATA[  Industry Risk Ratings Synopsis   This Industry Risk Ratings report from IBISWorld evaluates the inherent risks associated with the Chiropractors in the US industry. Industry Risk is assumed to be 'the difficulty, or otherwise, of the business operating environment'.  The report looks at the operational risk associated with this industry. Three types of risk are recognized in our analysis. These are: risk arising from within the industry itself (structural risk), risks arising from the expected future performance of the industry (growth risk) and risk arising from forces external to the industry (external sensitivity risk).  This approach is new in that it analyses non-financial information surrounding each industry. Industries are scored on a 9-point scale, where 1 represents the lowest risk and 9 the highest. The Industry Risk score measures expected Industry Risk over the coming 12-18 months.   Industry Definition   This industry comprises establishments of practitioners having the degree of DC (Doctor of Chiropractic) primarily engaged in ]]></description>
<pubDate>Sat, 17 Oct 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>Direct Mail Advertising in the US - Industry Risk Rating Report</title>
<link>http://www.mindbranch.com/products/R538-31060.html</link>
<description> <![CDATA[  Industry Risk Ratings Synopsis   This Industry Risk Ratings report from IBISWorld evaluates the inherent risks associated with the Direct Mail Advertising in the US industry. Industry Risk is assumed to be 'the difficulty, or otherwise, of the business operating environment'.  The report looks at the operational risk associated with this industry. Three types of risk are recognized in our analysis. These are: risk arising from within the industry itself (structural risk), risks arising from the expected future performance of the industry (growth risk) and risk arising from forces external to the industry (external sensitivity risk).  This approach is new in that it analyses non-financial information surrounding each industry. Industries are scored on a 9-point scale, where 1 represents the lowest risk and 9 the highest. The Industry Risk score measures expected Industry Risk over the coming 12-18 months.   Industry Definition   Direct mail advertisers distribute advertising materials (e.g. coupons, flyers, samples etc.) or specialties (e.g. key ]]></description>
<pubDate>Sat, 17 Oct 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>Health Stores in the US - Industry Risk Rating Report</title>
<link>http://www.mindbranch.com/products/R538-30877.html</link>
<description> <![CDATA[  Industry Risk Ratings Synopsis   This Industry Risk Ratings report from IBISWorld evaluates the inherent risks associated with the Health Stores in the US industry. Industry Risk is assumed to be 'the difficulty, or otherwise, of the business operating environment'.  The report looks at the operational risk associated with this industry. Three types of risk are recognized in our analysis. These are: risk arising from within the industry itself (structural risk), risks arising from the expected future performance of the industry (growth risk) and risk arising from forces external to the industry (external sensitivity risk).  This approach is new in that it analyses non-financial information surrounding each industry. Industries are scored on a 9-point scale, where 1 represents the lowest risk and 9 the highest. The Industry Risk score measures expected Industry Risk over the coming 12-18 months.   Industry Definition   This industry comprises companies primarily engaged in retailing health and personal care items (except drugs, medicines, ]]></description>
<pubDate>Sat, 17 Oct 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>Prescription Drug Wholesaling in the US - Industry Risk Rating Report</title>
<link>http://www.mindbranch.com/products/R538-30821.html</link>
<description> <![CDATA[  Industry Risk Ratings Synopsis   This Industry Risk Ratings report from IBISWorld evaluates the inherent risks associated with the Prescription Drug Wholesaling in the US industry. Industry Risk is assumed to be 'the difficulty, or otherwise, of the business operating environment'.  The report looks at the operational risk associated with this industry. Three types of risk are recognized in our analysis. These are: risk arising from within the industry itself (structural risk), risks arising from the expected future performance of the industry (growth risk) and risk arising from forces external to the industry (external sensitivity risk).  This approach is new in that it analyses non-financial information surrounding each industry. Industries are scored on a 9-point scale, where 1 represents the lowest risk and 9 the highest. The Industry Risk score measures expected Industry Risk over the coming 12-18 months.   Industry Definition   Prescription drug wholesalers sell biological and medical products, botanical drugs and herbs, and pharmaceutical products, ]]></description>
<pubDate>Sat, 17 Oct 2009 00:00:00 EST</pubDate>
</item>
</channel>
</rss>
